

K082983

**510(k) Summary - ResScan-Pro****JAN - 2 2009****Date Prepared** 30<sup>th</sup> Sept, 2008

**Official Contact** Dr Lionel King  
V.P., Quality Assurance & Regulatory Affairs  
ResMed Ltd  
1 Elizabeth Macarthur Drive  
Bella Vista NSW 2153  
Australia

Tel: +61 (2) 8884 2243

Fax: +61 (2) 8884 2000

**Classification Reference** 21 CFR 868.5905**Product Code** 73 BZD**Common/Usual Name** Non continuous ventilator (IPPB).**Proprietary Name** ResScan-Pro**Predicate Device(s)** ResScan (K050775)**Reason for submission** New Device

**Indication for Use**

ResScan-Pro is intended to augment the standard follow-up care of patients by providing transfer of machine and therapeutic information, including the ability to remotely change settings.

It is intended to be used by Clinicians in conjunction with ResMed compatible flow generators.

**Substantial Equivalence**

The new device has the following similarities to the previously cleared predicate device.

- Similar intended use
- Same operating principle
- Similar technologies
- Same manufacturing process

Design and Verification activities were performed on the ResScan-Pro system as a result of the risk analysis and design requirements. All tests confirmed the product met the predetermined acceptance criteria. ResMed has determined that the new device is substantially equivalent to the predicate device. ResScan-Pro has not altered the safety and effectiveness when used for patient compliance management as an adjunct with ResMed flow generators that have software incorporating proprietary communication protocol. The new device complies with the applicable requirements referenced in the FDA guidance documents:

- FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005)
- FDA Off-the-Shelf Software Use in Medical Devices (September 9, 1999)

**Device Description**

The performance and functional characteristics of ResScan-Pro includes all the user friendly features of the predicate device.

ResScan-Pro allows the clinician to:

- Download, view and store patient and machine details from a ResMed Flow Generator
- Create and print reports on patient and machine details
- Transfer treatment parameters to a ResMed Flow Generator

**Conclusion**

The ResScan-Pro System is substantially equivalent to the predicate device, ResScan (K050775).

---



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JAN - 2 2009

ResMed Limited  
C/O Mr. David D'Cruz  
Vice President, Clinical & Regulatory Affairs  
ResMed Corporation  
14040 Danielson Street  
Poway, California 92064-6857

Re: K082983

Trade/Device Name: ResScan-Pro  
Regulation Number: 21 CFR 868.5905  
Regulation Name: Noncontinuous Ventilator (IPPB)  
Regulatory Class: II  
Product Code: BZD  
Dated: September 30, 2008  
Received: October 6, 2008

Dear Mr. D'Cruz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Chiu Lin", is written over a horizontal line.

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,  
Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and  
Radiological Health

Enclosure

## Indication for Use

510(k) Number (if known):

Device Name: ResScan-Pro

## Indication for Use

ResScan-Pro is intended to augment the standard follow-up care of patients by providing transfer of machine and therapeutic information, including the ability to remotely change settings.

It is intended to be used by Clinicians in conjunction with ResMed compatible flow generators.

Prescription Use ☒

AND/OR


Over-The-Counter Use ☐

(Part 21 CFR 801 Subpart D)

(Part 21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH; Office of Device Evaluation (ODE)



Page 1 of 1

(Division Sign-Off)

Division of Anesthesiology, General Hospital  
Infection Control, Dental Devices

0(k) Number:

K082 983